{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:55:34Z","timestamp":1790780134434,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sichuan Science and Technology program","award":["2023YFS0133"],"award-info":[{"award-number":["2023YFS0133"]}]},{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"publisher","award":["3502Z202374035"],"award-info":[{"award-number":["3502Z202374035"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Program of Chengdu","award":["2024-YF05-00487-SN"],"award-info":[{"award-number":["2024-YF05-00487-SN"]}]},{"name":"Science and Technology Program of Tibet Autonomous Region","award":["XZ202401RK0005"],"award-info":[{"award-number":["XZ202401RK0005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04668-9","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:25:44Z","timestamp":1783423544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glutathione-depleting self-immolative nanoparticles boost cuproptosis-driven metalloimmunotherapy for triple-negative breast cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Yunhai","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunke","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"4668_CR1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N. Pembrolizumab for early triple-negative breast cancer. New Engl J Med. 2020;382:810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"New Engl J Med"},{"key":"4668_CR2","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309\u201337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020.","journal-title":"Cell"},{"key":"4668_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The next decade of immune checkpoint therapy. Cancer Discov. 2021;11:838\u201357. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1680.","journal-title":"Cancer Discov"},{"key":"4668_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561\u201384. https:\/\/doi.org\/10.1038\/nrd4591.","journal-title":"Nat Rev Drug Discov"},{"key":"4668_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172.","journal-title":"Science"},{"key":"4668_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113. https:\/\/doi.org\/10.1038\/s41571-021-00565-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"4668_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","volume":"621","author":"XQ Wang","year":"2023","unstructured":"Wang XQ, Danenberg E, Huang C-S, Egle D, Callari M, Bermejo B, Dugo M, Zamagni C, Thill M, Anton A. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature. 2023;621:868\u201376. https:\/\/doi.org\/10.1038\/s41586-023-06498-3.","journal-title":"Nature"},{"key":"4668_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-020-6668-z","volume":"20","author":"G Gao","year":"2020","unstructured":"Gao G, Wang Z, Qu X, Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20:179. https:\/\/doi.org\/10.1186\/s12885-020-6668-z.","journal-title":"BMC Cancer"},{"key":"4668_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris MA, Savas P, Virassamy B, O\u2019Malley MM, Kay J, Mueller SN, Mackay LK, Salgado R, Loi S. Towards targeting the breast cancer immune microenvironment. Nat Rev Cancer. 2024;24:554\u201377. https:\/\/doi.org\/10.1038\/s41568-024-00714-6.","journal-title":"Nat Rev Cancer"},{"key":"4668_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Henschel V, Molinero L, Chui SY. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(19)30689-8.","journal-title":"Lancet Oncol"},{"key":"4668_CR11","doi-asserted-by":"publisher","first-page":"eado8275","DOI":"10.1126\/sciadv.ado8275","volume":"10","author":"Q Shen","year":"2024","unstructured":"Shen Q, Murakami K, Sotov V, Butler M, Ohashi PS, Reedijk M. Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer. Sci Adv. 2024;10:eado8275. https:\/\/doi.org\/10.1126\/sciadv.ado8275.","journal-title":"Sci Adv"},{"key":"4668_CR12","doi-asserted-by":"publisher","first-page":"eadd8564","DOI":"10.1126\/sciadv.add8564","volume":"9","author":"L Vornholz","year":"2023","unstructured":"Vornholz L, Isay SE, Kurgyis Z, Strobl DC, Loll P, Mosa MH, Luecken MD, Sterr M, Lickert H, Winter C. Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy. Sci Adv. 2023;9:eadd8564. https:\/\/doi.org\/10.1126\/sciadv.add8564.","journal-title":"Sci Adv"},{"key":"4668_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fimmu.2020.00069","volume":"11","author":"M Yarmarkovich","year":"2020","unstructured":"Yarmarkovich M, Farrel A, Sison A III, Di Marco M, Raman P, Parris JL, Monos D, Lee H, Stevanovic S, Maris JM. Immunogenicity and immune silence in human cancer. Front Immunol. 2020;11:69. https:\/\/doi.org\/10.3389\/fimmu.2020.00069.","journal-title":"Front Immunol"},{"key":"4668_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509\u201328. https:\/\/doi.org\/10.1038\/s41573-021-00345-8.","journal-title":"Nat Rev Drug Discov"},{"key":"4668_CR15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41551-024-01221-7","volume":"8","author":"X Sun","year":"2024","unstructured":"Sun X, Zhou X, Shi X, Abed OA, An X, Lei YL, Moon JJ. Strategies for the development of metalloimmunotherapies. Nat Biomed Eng. 2024;8:1073\u201391. https:\/\/doi.org\/10.1038\/s41551-024-01221-7.","journal-title":"Nat Biomed Eng"},{"key":"4668_CR16","doi-asserted-by":"publisher","first-page":"e202310178","DOI":"10.1002\/anie.202310178","volume":"62","author":"S He","year":"2023","unstructured":"He S, Yu J, Xu M, Zhang C, Xu C, Cheng P, Pu K. A semiconducting iron-chelating nano\u2010immunomodulator for specific and sensitized sono\u2010metallo\u2010immunotherapy of cancer. Angew Chem Int Edit. 2023;62:e202310178. https:\/\/doi.org\/10.1002\/anie.202310178.","journal-title":"Angew Chem Int Edit"},{"key":"4668_CR17","doi-asserted-by":"publisher","first-page":"2206915","DOI":"10.1002\/adma.202206915","volume":"34","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhao J, Hu X, Wang C, Jia Y, Zhu C, Xie S, Lee J, Li F, Ling D. A peritumorally injected immunomodulating adjuvant elicits robust and safe metalloimmunotherapy against solid tumors. Adv Mater. 2022;34:2206915. https:\/\/doi.org\/10.1002\/adma.202206915.","journal-title":"Adv Mater"},{"key":"4668_CR18","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, Eaton JK, Frenkel E, Kocak M, Corsello SM, Lutsenko S, Kanarek N, Santagata S, Golub TR. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254\u201361. https:\/\/doi.org\/10.1126\/science.abf0529.","journal-title":"Science"},{"key":"4668_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","volume":"7","author":"L Chen","year":"2022","unstructured":"Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Tar. 2022;7:378. https:\/\/doi.org\/10.1038\/s41392-022-01229-y.","journal-title":"Signal Transduct Tar"},{"key":"4668_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1039\/d5cs00083a","volume":"13","author":"L Mao","year":"2025","unstructured":"Mao L, Lu J, Wen X, Song Z, Sun C, Zhao Y, Huang F, Chen S, Jiang D, Che W. Cuproptosis: mechanisms and nanotherapeutic strategies in cancer and beyond. Chem Soc Rev. 2025;13:54. https:\/\/doi.org\/10.1039\/d5cs00083a.","journal-title":"Chem Soc Rev"},{"key":"4668_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41571-024-00876-0","volume":"21","author":"D Tang","year":"2024","unstructured":"Tang D, Kroemer G, Kang R. Targeting cuproplasia and cuproptosis in cancer. Nat Rev Clin Oncol. 2024;21:370\u201388. https:\/\/doi.org\/10.1038\/s41571-024-00876-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"4668_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12943-025-02225-w","volume":"24","author":"L Zhao","year":"2025","unstructured":"Zhao L, Gui Y, Cai J, Deng X. Biometallic ions and derivatives: a new direction for cancer immunotherapy. Mol Cancer. 2025;24:17. https:\/\/doi.org\/10.1186\/s12943-025-02225-w.","journal-title":"Mol Cancer"},{"key":"4668_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12943-024-02130-8","volume":"23","author":"X Zhang","year":"2024","unstructured":"Zhang X, Tang B, Luo J, Yang Y, Weng Q, Fang S, Zhao Z, Tu J, Chen M, Ji J. Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope. Mol Cancer. 2024;23:255. https:\/\/doi.org\/10.1186\/s12943-024-02130-8.","journal-title":"Mol Cancer"},{"key":"4668_CR24","doi-asserted-by":"publisher","first-page":"2408106","DOI":"10.1002\/advs.202408106","volume":"12","author":"Z Sun","year":"2025","unstructured":"Sun Z, Xu H, Lu G, Yang C, Gao X, Zhang J, Liu X, Chen Y, Wang K, Guo J. AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple-Negative Breast Cancer. Adv Sci. 2025;12:2408106. https:\/\/doi.org\/10.1002\/advs.202408106.","journal-title":"Adv Sci"},{"key":"4668_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41565-021-00950-z","volume":"16","author":"Z Wang","year":"2021","unstructured":"Wang Z, Little N, Chen J, Lambesis KT, Le KT, Han W, Scott AJ, Lu J. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nat Nanotechnol. 2021;16:1130\u201340. https:\/\/doi.org\/10.1038\/s41565-021-00950-z.","journal-title":"Nat Nanotechnol"},{"key":"4668_CR26","doi-asserted-by":"publisher","first-page":"2400652","DOI":"10.1002\/adhm.202400652","volume":"13","author":"J Lu","year":"2024","unstructured":"Lu J, Miao Y, Li Y. Cuproptosis: Advances in Stimulus-Responsive Nanomaterials for Cancer Therapy. Adv Healthc Mater. 2024;13:2400652. https:\/\/doi.org\/10.1002\/adhm.202400652.","journal-title":"Adv Healthc Mater"},{"key":"4668_CR27","doi-asserted-by":"publisher","first-page":"eadk0716","DOI":"10.1126\/sciadv.adk0716","volume":"10","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Pan Z, Li Q, Huang Q, Shi L, Liu Y. Rational design of ICD-inducing nanoparticles for cancer immunotherapy. Sci Adv. 2024;10:eadk0716. https:\/\/doi.org\/10.1126\/sciadv.adk0716.","journal-title":"Sci Adv"},{"key":"4668_CR28","doi-asserted-by":"publisher","first-page":"1236063","DOI":"10.3389\/fimmu.2023.1236063","volume":"14","author":"L Gao","year":"2023","unstructured":"Gao L, Zhang A. Copper-instigated modulatory cell mortality mechanisms and progress in oncological treatment investigations. Front Immunol. 2023;14:1236063. https:\/\/doi.org\/10.3389\/fimmu.2023.1236063.","journal-title":"Front Immunol"},{"key":"4668_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12943-025-02445-0","volume":"24","author":"Z Jing","year":"2025","unstructured":"Jing Z, Huang W, Mei J, Bhushan S, Wu X, Yan C, Zheng H, Yang Y. Advances in novel cell death mechanisms in breast cancer: intersecting perspectives on ferroptosis, cuproptosis, disulfidptosis, and pyroptosis. Mol Cancer. 2025;24:224. https:\/\/doi.org\/10.1186\/s12943-025-02445-0.","journal-title":"Mol Cancer"},{"key":"4668_CR30","doi-asserted-by":"publisher","unstructured":"Wang Y, Wang J, Jiang J, Zhang W, Sun L, Ge Q, Li C, Li X, Li X, Shi S. Identification of cuproptosis-related miRNAs in triple-negative breast cancer and analysis of the miRNA\u2013mRNA regulatory network. Heliyon. 2024;10. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28242.","DOI":"10.1016\/j.heliyon.2024.e28242"},{"key":"4668_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.62347\/LOYI1808","volume":"17","author":"Z-H Luo","year":"2024","unstructured":"Luo Z-H, Zhou B, Yu J-Y, Li H, Li Z, Ma S-Q. Role of SLC31A1 in prognosis and immune infiltration in breast cancer: a novel insight. Int J Clin Exp Patho. 2024;17:329. https:\/\/doi.org\/10.62347\/LOYI1808.","journal-title":"Int J Clin Exp Patho"},{"key":"4668_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12859-023-05348-3","volume":"24","author":"B Shi","year":"2023","unstructured":"Shi B, Zhang W, Wang T, Cui Z. The therapeutic and prognostic role of cuproptosis-related genes in triple negative breast cancer. BMC Bioinformatics. 2023;24:223. https:\/\/doi.org\/10.1186\/s12859-023-05348-3.","journal-title":"BMC Bioinformatics"},{"key":"4668_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41422-022-00653-7","volume":"32","author":"D Tang","year":"2022","unstructured":"Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32:417\u20138. https:\/\/doi.org\/10.1038\/s41422-022-00653-7.","journal-title":"Cell Res"},{"key":"4668_CR34","doi-asserted-by":"publisher","first-page":"2401646","DOI":"10.1002\/adhm.202401646","volume":"13","author":"N Wang","year":"2024","unstructured":"Wang N, Liu Y, Peng D, Zhang Q, Zhang Z, Xu L, Yin L, Zhao X, Lu Z, Peng J. Copper-based composites nanoparticles improve triple\u2010negative breast cancer treatment with induction of apoptosis\u2010cuproptosis and immune activation. Adv Healthc Mater. 2024;13:2401646. https:\/\/doi.org\/10.1002\/adhm.202401646.","journal-title":"Adv Healthc Mater"},{"key":"4668_CR35","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.nantod.2023.101911","volume":"51","author":"Q-X Huang","year":"2023","unstructured":"Huang Q-X, Liang J-L, Chen Q-W, Jin X-K, Niu M-T, Dong C-Y, Zhang X-Z. Metal-organic framework nanoagent induces cuproptosis for effective immunotherapy of malignant glioblastoma. Nano Today. 2023;51:101911. https:\/\/doi.org\/10.1016\/j.nantod.2023.101911.","journal-title":"Nano Today"},{"key":"4668_CR36","doi-asserted-by":"publisher","first-page":"2212267","DOI":"10.1002\/adma.202212267","volume":"35","author":"B Guo","year":"2023","unstructured":"Guo B, Yang F, Zhang L, Zhao Q, Wang W, Yin L, Chen D, Wang M, Han S, Xiao H. Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with \u03b1PD-L1 for enhanced cancer immunotherapy. Adv Mater. 2023;35:2212267. https:\/\/doi.org\/10.1002\/adma.202212267.","journal-title":"Adv Mater"},{"key":"4668_CR37","doi-asserted-by":"publisher","first-page":"101585","DOI":"10.1016\/j.nantod.2022.101585","volume":"46","author":"Y Yang","year":"2022","unstructured":"Yang Y, Ge J, Li G, Lei H, Chen L, Gong Y, Zhong X, Wang L, Dai Y, Tang W. Manganese-doping titanium disulfide cascade nanobioreactors for sequential gas-sonodynamic strategy with immune checkpoint blockade therapy of cancer. Nano Today. 2022;46:101585. https:\/\/doi.org\/10.1016\/j.nantod.2022.101585.","journal-title":"Nano Today"},{"key":"4668_CR38","doi-asserted-by":"publisher","first-page":"2204733","DOI":"10.1002\/adma.202204733","volume":"34","author":"Y Xu","year":"2022","unstructured":"Xu Y, Liu SY, Zeng L, Ma H, Zhang Y, Yang H, Liu Y, Fang S, Zhao J, Xu Y. An enzyme-engineered nonporous copper (I) coordination polymer nanoplatform for cuproptosis\u2010based synergistic cancer therapy. Adv Mater. 2022;34:2204733. https:\/\/doi.org\/10.1002\/adma.202204733.","journal-title":"Adv Mater"},{"key":"4668_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12951-023-01998-w","volume":"21","author":"Z Rao","year":"2023","unstructured":"Rao Z, Xia Y, Jia Q, Zhu Y, Wang L, Liu G, Liu X, Yang P, Ning P, Zhang R. Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination. J Nanobiotechnol. 2023;21:265. https:\/\/doi.org\/10.1186\/s12951-023-01998-w.","journal-title":"J Nanobiotechnol"},{"key":"4668_CR40","doi-asserted-by":"publisher","first-page":"11251","DOI":"10.1039\/c6cc06437j","volume":"52","author":"C Bonduelle","year":"2016","unstructured":"Bonduelle C, Oliveira H, Gauche C, Huang J, Heise A, Lecommandoux S. Multivalent effect of glycopolypeptide based nanoparticles for galectin binding. Chem Commun. 2016;52:11251\u20134. https:\/\/doi.org\/10.1039\/c6cc06437j.","journal-title":"Chem Commun"},{"key":"4668_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA, Elia A, Berger T, Cescon DW, Adeoye A, Br\u00fcstle A, Molyneux SD, Mason JM, Li WY, Yamamoto K, Wakeham A, Berman HK, Khokha R, Done SJ, Kavanagh TJ, Lam C-W, Mak TW. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 2015;27:211\u201322. https:\/\/doi.org\/10.1016\/j.ccell.2014.11.019.","journal-title":"Cancer Cell"},{"key":"4668_CR42","doi-asserted-by":"publisher","unstructured":"John WE, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","DOI":"10.1038\/nri3862"},{"key":"4668_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.immuni.2017.03.019","volume":"46","author":"TW Mak","year":"2017","unstructured":"Mak TW, Grusdat M, Duncan GS, Dostert C, Nonnenmacher Y, Cox M, Binsfeld C, Hao Z, Br\u00fcstle A, Itsumi M, J\u00e4ger C, Chen Y, Pinkenburg O, Camara B, Ollert M, Bindslev-Jensen C, Vasiliou V, Gorrini C, Lang PA, Lohoff M, Harris IS, Hiller K, Brenner D. Glutathione primes T cell metabolism for inflammation. Immunity. 2017;46:675\u201389. https:\/\/doi.org\/10.1016\/j.immuni.2017.03.019.","journal-title":"Immunity"},{"key":"4668_CR44","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, Saleh SMI, Zhao H, Souleimanova M, Johnson RM. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019;129:1785\u2013800. https:\/\/doi.org\/10.1172\/JCI96313.","journal-title":"J Clin Invest"},{"key":"4668_CR45","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Di\u00e9ras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. Jnci-J Natl Cancer I. 2021;113:1005\u201316. https:\/\/doi.org\/10.1093\/jnci\/djab004.","journal-title":"Jnci-J Natl Cancer I"},{"key":"4668_CR46","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im S-A. Shaw Wright, Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl J Med. 2018;379:2108\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1809615.","journal-title":"New Engl J Med"},{"key":"4668_CR47","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10555-021-09972-4","volume":"40","author":"AL Heeke","year":"2021","unstructured":"Heeke AL, Tan AR. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer Metast Rev. 2021;40:537\u201347. https:\/\/doi.org\/10.1007\/s10555-021-09972-4.","journal-title":"Cancer Metast Rev"},{"key":"4668_CR48","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-16-2569","volume":"23","author":"RH Vonderheide","year":"2017","unstructured":"Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for breast cancer: what are we missing? Clin Cancer Res. 2017;23:2640\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2569.","journal-title":"Clin Cancer Res"},{"key":"4668_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12943-021-01317-7","volume":"20","author":"J-Y Li","year":"2021","unstructured":"Li J-Y, Chen Y-P, Li Y-Q, Liu N, Ma J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer. 2021;20:27. https:\/\/doi.org\/10.1186\/s12943-021-01317-7.","journal-title":"Mol Cancer"},{"key":"4668_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12943-023-01732-y","volume":"22","author":"J Xie","year":"2023","unstructured":"Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023;22:46. https:\/\/doi.org\/10.1186\/s12943-023-01732-y.","journal-title":"Mol Cancer"},{"key":"4668_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/imr.13276","volume":"321","author":"WQ Liu","year":"2024","unstructured":"Liu WQ, Lin WR, Yan L, Xu WH, Yang J. Copper homeostasis and cuproptosis in cancer immunity and therapy. Immunol Rev. 2024;321:211\u201327. https:\/\/doi.org\/10.1111\/imr.13276.","journal-title":"Immunol Rev"},{"key":"4668_CR52","doi-asserted-by":"publisher","first-page":"1168769","DOI":"10.3389\/fonc.2023.1168769","volume":"13","author":"Y Quan","year":"2023","unstructured":"Quan Y, Li W, Yan R, Cheng J, Xu H, Chen L. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1. Front Oncol. 2023;13:1168769. https:\/\/doi.org\/10.3389\/fonc.2023.1168769.","journal-title":"Front Oncol"},{"key":"4668_CR53","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12951-024-02859-w","volume":"22","author":"X Meng","year":"2024","unstructured":"Meng X, Shen Y, Zhao H, Lu X, Wang Z, Zhao Y. Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review. J Nanobiotechnol. 2024;22:587. https:\/\/doi.org\/10.1186\/s12951-024-02859-w.","journal-title":"J Nanobiotechnol"},{"key":"4668_CR54","doi-asserted-by":"publisher","first-page":"841814","DOI":"10.3389\/fmolb.2022.841814","volume":"9","author":"V Oliveri","year":"2022","unstructured":"Oliveri V. Selective targeting of cancer cells by copper ionophores: an overview. Front Mol Biosci. 2022;9:841814. https:\/\/doi.org\/10.3389\/fmolb.2022.841814.","journal-title":"Front Mol Biosci"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04668-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04668-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04668-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:03:15Z","timestamp":1790776995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04668-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4668"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04668-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures were approved by the ethical committee of the West China Hospital of Sichuan University (No. 20240311016). All experimental procedures were conducted in accordance with the relevant guidelines and regulations for animal welfare and ethics.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"912"}}